Development of imiquimod-loaded mucoadhesive films for oral dysplasia.
暂无分享,去创建一个
[1] Zhonggui He,et al. Preparation, characterization and in vivo evaluation of formulation of repaglinide with hydroxypropyl-β-cyclodextrin. , 2006, International journal of pharmaceutics.
[2] S. Schwendeman,et al. Development and In Vitro-In Vivo Evaluation of Fenretinide-Loaded Oral Mucoadhesive Patches for Site-Specific Chemoprevention of Oral Cancer , 2011, Pharmaceutical Research.
[3] A. Mahmoud,et al. Formulation of Indomethacin Eye Drops via Complexation with Cyclodextrins , 2011, Current eye research.
[4] S. Weintraub,et al. Heat generates oxidized linoleic acid metabolites that activate TRPV1 and produce pain in rodents. , 2010, The Journal of clinical investigation.
[5] R. Gaud,et al. FORMULATION OF A WATER SOLUBLE MUCOADHESIVE FILM OF LYCOPENE FOR TREATMENT OF LEUKOPLAKIA , 2010 .
[6] K. Cho,et al. A case of erythroplasia of queyrat treated with imiquimod 5% cream and excision. , 2009, Annals of dermatology.
[7] David S Jones,et al. Rheological, mechanical and mucoadhesive properties of thermoresponsive, bioadhesive binary mixtures composed of poloxamer 407 and carbopol 974P designed as platforms for implantable drug delivery systems for use in the oral cavity. , 2009, International journal of pharmaceutics.
[8] Jashin J. Wu,et al. Off-label indications for imiquimod. , 2009, Dermatology online journal.
[9] S. Mutalik,et al. Development of mucoadhesive buccal films for the treatment of oral sub-mucous fibrosis: a preliminary study , 2009, Pharmaceutical development and technology.
[10] B. Thiers. Treatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod , 2009 .
[11] V. Kadam,et al. Mucoadhesive Bilayered Patches for Administration of Sumatriptan Succinate , 2008, AAPS PharmSciTech.
[12] Y. Pore,et al. Effect of β-cyclodextrin complexation on physicochemical properties of zaleplon , 2008 .
[13] V. Khutoryanskiy,et al. Mucoadhesive and elastic films based on blends of chitosan and hydroxyethylcellulose. , 2008, Macromolecular bioscience.
[14] T. Bieber,et al. Successful treatment of extensive human papillomavirus‐associated oral leucoplakia with imiquimod , 2007, The British journal of dermatology.
[15] S. Baboota,et al. Physicochemical characterization, in vitro dissolution behavior, and pharmacodynamic studies of rofecoxib-cyclodextrin inclusion compounds. Preparation and properties of rofecoxib hydroxypropyl β-cyclodextrin inclusion complex: A technical note , 2005, AAPS PharmSciTech.
[16] R. Kaufmann,et al. Topical imiquimod: effectiveness in intraepithelial melanoma of oral mucosa. , 2006, The Lancet. Oncology.
[17] P. McCarron,et al. Design and physicochemical characterisation of a bioadhesive patch for dose-controlled topical delivery of imiquimod. , 2006, International journal of pharmaceutics.
[18] Jianqing Gao,et al. Preparation, characterization and in vivo evaluation of formulation of baicalein with hydroxypropyl-beta-cyclodextrin. , 2006, International journal of pharmaceutics.
[19] A. Chakrabarty,et al. Aphthous ulcers associated with imiquimod and the treatment of actinic cheilitis. , 2005, Journal of the American Academy of Dermatology.
[20] Carlo Rossi,et al. Development of mucoadhesive patches for buccal administration of ibuprofen. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[21] L. Fenart,et al. Behavior of α-, β-, and γ-Cyclodextrins and Their Derivatives on an in Vitro Model of Blood-Brain Barrier , 2004, Journal of Pharmacology and Experimental Therapeutics.
[22] L. Golitz,et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. , 2004, Journal of the American Academy of Dermatology.
[23] Roger A. Rajewski,et al. Cyclodextrins: Their Future in Drug Formulation and Delivery , 1997, Pharmaceutical Research.
[24] Ping I. Lee,et al. A New Bioerodible Polymer Insert for the Controlled Release of Metronidazole , 1994, Pharmaceutical Research.
[25] A. Rebora,et al. Occlusive medication with imiquimod in Bowen's disease. , 2004, Acta dermato-venereologica.
[26] W. Sterry,et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low‐frequency dosing with and without occlusion , 2002, The British journal of dermatology.
[27] C. Twelves,et al. Oral cancer treatment: developments in chemotherapy and beyond , 2002, British Journal of Cancer.
[28] R. Sinisterra,et al. An effective anticonvulsant prepared following a host-guest strategy that uses hydroxypropyl-beta-cyclodextrin and benzaldehyde semicarbazone. , 2002, Biochemical and biophysical research communications.
[29] T. Day,et al. Oral Cancer and Precancerous Lesions , 2002, CA: a cancer journal for clinicians.
[30] K. Chowdary,et al. Nimesulide and β-Cyclodextrin Inclusion Complexes: Physicochemical Characterization and Dissolution Rate Studies , 2000, Drug development and industrial pharmacy.
[31] C. Wong,et al. An in-vitro method for buccal adhesion studies: importance of instrument variables. , 1999, International journal of pharmaceutics.
[32] M. Jozwiakowski,et al. Development of a topically active imiquimod formulation. , 1999, Pharmaceutical development and technology.
[33] J. Szejtli. Introduction and General Overview of Cyclodextrin Chemistry , 1998 .
[34] J. Szejtli. Introduction and General Overview of Cyclodextrin Chemistry. , 1998, Chemical reviews.
[35] F. Hirayama,et al. Cyclodextrin Drug Carrier Systems. , 1998, Chemical reviews.
[36] Javed Ali,et al. Mucoadhesive Drug Delivery Systems , 1997 .
[37] W. Galey,et al. The in vitro permeability of skin and buccal mucosa to selected drugs and tritiated water. , 1976, The Journal of investigative dermatology.
[38] T. Higuchi,et al. Phase solubility techniques , 1965 .